Advertisement

Organisation › Details
DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases. DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). *
![]() |
Start | 2002-01-01 established |
![]() |
Industry | Viaskin® allergy treatment |
Industry 2 | topical drug delivery technology | |
![]() |
Person | Benhamou, Pierre-Henri (DBV Technologies 201508 CEO + Board Director of Biotech France) |
Person 2 | Donne, Nathalie (DBV Technologies 201507 Director CorpComm + Business Development) | |
![]() |
Region | Bagneux, Hauts-de-Seine |
Country | France | |
Street | 80/84 rue des Meuniers | |
City | 92220 Bagneux | |
Tel | +33-1-5542-7878 | |
Address record changed: 2018-07-24 | ||
Basic data | Employees | D: 101 to 500 (2017-12-31) |
Currency | EUR | |
Annual sales | 11,909,000 (income, operating, consolidated (2017) 2017-12-31) | |
Profit | -147,693,000 (2016-12-31) | |
Cash | 137,880,000 (2017-12-31) | |
* Document for �About Section�: DBV Technologies S.A.. (3/15/17). "Press Release: DBV Technologies Reports Full Year 2016 Financial Results". | ||
Record changed: 2018-10-30 |
Advertisement

More documents for DBV Technologies S.A. (Euronext Paris: DBV + Nasdaq Global Select Market: DBVT)
- [1] DBV Technologies S.A.. (3/26/18). "Press Release: DBV Technologies Announces Closing of Underwriters’ Option to Purchase Additional Shares in Global Offering". Montrouge....
- [2] DBV Technologies S.A.. (3/23/18). "Press Release: DBV Technologies Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares". Montrouge....
- [3] DBV Technologies S.A.. (3/21/18). "Press Release: DBV Technologies Announces Pricing of $150.0 million (€122.5 million) Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares". Montrouge....
- [4] DBV Technologies S.A.. (3/20/18). "Press Release: DBV Technologies Announces the Launch of a Proposed Global Offering of Ordinary Shares, Which May Be in the Form of American Depositary Shares". Montrouge....
- [5] DBV Technologies S.A.. (3/14/18). "Press Release: DBV Technologies Reports Full Year 2017 Financial Results". Montrouge....
- [6] DBV Technologies S.A.. (3/7/18). "Press Release: DBV Technologies to Present at the Barclays Global Healthcare Conference". Montrouge....
- [7] DBV Technologies S.A.. (2/26/18). "Press Release: DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients". Montrouge....
- [8] DBV Technologies S.A.. (10/20/17). "Press Release: DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut Allergic Patients Four to 11 Years of Age"....
- [9] DBV Technologies S.A.. (9/1/17). "Press Release: DBV Technologies to Attend Upcoming Investor Conferences". Montrouge....
- [10] DBV Technologies S.A.. (8/29/17). "Press Release: DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut". Montrouge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top